Alphatec Holdings, Inc. (ATEC) is a Healthcare stock trading at $9.28 (as of 2026-08-20), with a market capitalization of $1.43B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Alphatec Holdings, Inc. is a medical technology company focused on technologies used in surgical treatment of spinal disorders. Its product portfolio includes systems such as SafeOp Neural InformatiX, Sigma transforaminal lumbar interbody fusion access, Invictus fixation and minimally invasive pedicle screw systems, and related spinal implant and accessory platforms used by clinicians in surgical procedures.
Understand Alphatec Holdings, Inc.: how it makes money
Alphatec Holdings designs and develops spinal surgical technologies and systems, selling products used in spinal disorder surgeries and related offerings such as its SafeOp Neural InformatiX platform and Sigma spinal fixation and access systems.
The profit engine is per-procedure product adoption, monetized as multiple spinal products are used per case and a large share of revenue comes from new products (including an observed biologics attachment rate).
Revenue by segment (latest quarter)
Surgical
$0.2B
EOS Imaging
$0.0B
Business quality (Weak): High gross margin (71.0%) but an operating loss (operating margin -11.8%), so execution on the cost base matters even if product economics look strong.
Bull case
Multiple products can be adopted in a single surgery (Average Products per Procedure 2.4, Blended Average Number of Products per Case 2.2), supporting higher revenue per case: This creates a clearer growth lever than unit volume alone, because the business can expand its product mix within spinal procedures.
New products appear to dominate the revenue mix (Share of Revenue from New Products 87.0%, New Products Usage 84.0%): If that continues, it can support product relevancy and ongoing portfolio contribution.
Gross margin is strong (71.0%): That suggests core product economics are favorable, even though operating profitability is currently negative.
Bear case
Operating profitability is negative (operating margin -11.8%): This indicates costs are currently outweighing gross profit, so investors will want to understand what is driving operating expenses.
Surgical revenue is the dominant portion of sales (Surgical Revenue 0.18B out of 0.2B total revenue shown): If spinal procedure demand, adoption, or competitive dynamics weaken, overall results could be pressured.
International-related revenue appears immaterial in the provided breakdown (Revenue Related to International Distribution Agreement 0.0, International Supply Agreement Revenue 0.0): That may limit diversification benefits if the business is concentrated in regions that drive the bulk of surgical revenue.